Larvol Delta - Elixiron-Immunotherapeutics-Announces-Orphan-Drug-Designation-Granted-to-CSF1R-Inhibitor-EI1071-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis

EI1071 - Elixiron Immunotherap

https://www.globenewswire.com/news-release/2022/08/02/2490643/0/en/Elixiron-Immunotherapeutics-Announces-Orphan-Drug-Designation-Granted-to-CSF-1R-Inhibitor-EI-1071-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html

Aug 2, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev